Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish

Shares of Bristol-Myers Squibb Co BMY have lost more than 10 percent since the start of 2016 and are nearly flat over the past year. A lack of growth in Bristol-Myers' stock over the past year hasn't deterred the Vetr crowd. The crowd-sourced stock rating platform upgraded the stock's rating to 4.5-stars out of a possible 5-stars. In fact, shares have risen to $61.71 since the prior rating of 4.0-stars was issued 14 days ago. Related link: Here's how crowdsourced ratings can beat the market.

In addition to an upgrade to bull territory, 83 percent of the crowd's ratings are bullish and the crowd sourced price target of $69.74 implies a potential upside of nearly 14 percent. Héctor Garcia, a member of the Vetr crowd, commented 10 days ago that Bristol-Myers' stock is trading below its 50 and 200-day moving average. The crowd member added that while this may be a bullish signal, the current market condition for healthcare stocks is "less than favorable." As such, Bristol-Myers' stock is more appropriate for a longer-term investor that can stomach near-term volatility.